CC
LXEO icon

Corton Capital’s Lexeo Therapeutics LXEO Stock Holding History

Corton Capital’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,711
Closed -$44.1K – 379
2025
Q1 		$44.1K Sell
12,711
-1,060
-8% -$4.7K 0.15% 161
2024
Q4 		$90.6K Buy
+13,771
New +$108K 0.05% 353

Other funds holding LXEO

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Corton Capital's LXEO Position: Q2 2025 in Review

Corton Capital sold out of Lexeo Therapeutics (LXEO) in Q2 2025, closing a stake of 12,711 shares — an estimated $44.1K sold.

Corton Capital first reported a position in LXEO in Q4 2024 and held it in 2 quarters. The position peaked at $90.6K in Q4 2024. 90 funds tracked by Wall St. Rank hold LXEO as of Q2 2025.

  • Corton Capital reported no remaining Lexeo Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corton Capital sold 12,711 Lexeo Therapeutics shares in Q2 2025, an estimated $44.1K.
  • Corton Capital first reported a position in Lexeo Therapeutics in Q4 2024 and held it in 2 quarters.
  • Corton Capital's Lexeo Therapeutics position peaked at $90.6K in Q4 2024.
  • 90 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2025.

Based on Corton Capital's 13F filing for Q2 2025, filed 5 Aug 2025.